Tag: stemi

Genotype-Guided Antiplatelet Therapy Misses Mark

The observational extended study of the previously reported 12-month randomized TAILOR-PCI trial shows genotype-guided antiplatelet therapy after percutaneous coronary intervention (PCI) did not significantly reduce...

Arthritis Drug May Curb Myocardial Damage in Acute STEMI

Early use of tocilizumab (Actemra) does not reduce myocardial infarct size but modestly increases myocardial salvage in patients with acute ST-segment elevation myocardial infarction (STEMI),...

Target-Lesion Failure Reduced After MI With Biodegradable Stent

For a primary composite target-lesion failure outcome, a biodegradable polymer sirolimus-eluting stent showed superiority at 2 years over a durable polymer everolimus-eluting stent in patients...

Prior Beta Blockers Predict Extra HF Burden in Women With ACS

Beta blockers taken for hypertension may predispose women to worse outcomes, compared with men, when they later present with acute coronary syndromes (ACS), a registry...

Chewed Prasugrel for Primary PCI? Forget It!

Tirofiban is far superior to cangrelor at achieving rapid and potent inhibition of platelet aggregation in patients undergoing primary percutaneous coronary intervention for ST-elevation MI....

Signature STEMI Sign May Be Less Diagnostic in the COVID-19 Age

Editor’s note: Find the latest COVID-19 news and guidance in Medscape’s Coronavirus Resource Center. The signature electrocardiographic sign indicating ST-segment-elevation myocardial infarction (STEMI) may be...